Cargando…
Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
Background: Endobiliary radiofrequency ablation (RFA) is a promising treatment modality for patients with extrahepatic cholangiocarcinoma (eCCA). However, no study has investigated the combined use of endobiliary RFA and gemcitabine plus cisplatin (GC) chemotherapy. This study aimed to examine the f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029596/ https://www.ncbi.nlm.nih.gov/pubmed/35448156 http://dx.doi.org/10.3390/curroncol29040182 |
_version_ | 1784691917967065088 |
---|---|
author | Inoue, Tadahisa Naitoh, Itaru Kitano, Rena Ibusuki, Mayu Kobayashi, Yuji Sumida, Yoshio Nakade, Yukiomi Ito, Kiyoaki Yoneda, Masashi |
author_facet | Inoue, Tadahisa Naitoh, Itaru Kitano, Rena Ibusuki, Mayu Kobayashi, Yuji Sumida, Yoshio Nakade, Yukiomi Ito, Kiyoaki Yoneda, Masashi |
author_sort | Inoue, Tadahisa |
collection | PubMed |
description | Background: Endobiliary radiofrequency ablation (RFA) is a promising treatment modality for patients with extrahepatic cholangiocarcinoma (eCCA). However, no study has investigated the combined use of endobiliary RFA and gemcitabine plus cisplatin (GC) chemotherapy. This study aimed to examine the feasibility and efficacy of endobiliary RFA with GC therapy for patients with unresectable eCCA. Methods: The study outcomes included overall survival (OS), progression-free survival (PFS), time to recurrent biliary obstruction (RBO), and adverse events associated with the treatment. These parameters were retrospectively compared between 25 patients who underwent RFA with self-expandable metal stent (SEMS) placement followed by GC therapy (with-RFA group) and a control cohort of 25 patients who underwent SEMS placement alone and GC therapy (without-RFA group). Results: The median time to RBO was significantly longer in the with-RFA group (10.7 versus 5.2 months, p = 0.048). The median OS was significantly higher in patients with locally advanced tumors in the with-RFA group (23.1 versus 16.6 months, p = 0.032), but did not differ significantly in patients with metastasis (11.4 versus 8.5 months, p = 0.180). Similarly, the median PFS was significantly higher in the with-RFA group in patients with locally advanced disease (10.1 versus 7.3 months, p = 0.015), while there was no significant difference in patients with metastasis (5.4 versus 4.4 months, p = 0.529). The rates of various toxicities did not differ significantly between the groups. Conclusions: Endobiliary RFA prolonged the patency period of uncovered SEMS combined with GC therapy in patients with eCCA. Although RFA also yielded survival benefits, its effect was restricted to locally advanced tumors. |
format | Online Article Text |
id | pubmed-9029596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90295962022-04-23 Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma Inoue, Tadahisa Naitoh, Itaru Kitano, Rena Ibusuki, Mayu Kobayashi, Yuji Sumida, Yoshio Nakade, Yukiomi Ito, Kiyoaki Yoneda, Masashi Curr Oncol Article Background: Endobiliary radiofrequency ablation (RFA) is a promising treatment modality for patients with extrahepatic cholangiocarcinoma (eCCA). However, no study has investigated the combined use of endobiliary RFA and gemcitabine plus cisplatin (GC) chemotherapy. This study aimed to examine the feasibility and efficacy of endobiliary RFA with GC therapy for patients with unresectable eCCA. Methods: The study outcomes included overall survival (OS), progression-free survival (PFS), time to recurrent biliary obstruction (RBO), and adverse events associated with the treatment. These parameters were retrospectively compared between 25 patients who underwent RFA with self-expandable metal stent (SEMS) placement followed by GC therapy (with-RFA group) and a control cohort of 25 patients who underwent SEMS placement alone and GC therapy (without-RFA group). Results: The median time to RBO was significantly longer in the with-RFA group (10.7 versus 5.2 months, p = 0.048). The median OS was significantly higher in patients with locally advanced tumors in the with-RFA group (23.1 versus 16.6 months, p = 0.032), but did not differ significantly in patients with metastasis (11.4 versus 8.5 months, p = 0.180). Similarly, the median PFS was significantly higher in the with-RFA group in patients with locally advanced disease (10.1 versus 7.3 months, p = 0.015), while there was no significant difference in patients with metastasis (5.4 versus 4.4 months, p = 0.529). The rates of various toxicities did not differ significantly between the groups. Conclusions: Endobiliary RFA prolonged the patency period of uncovered SEMS combined with GC therapy in patients with eCCA. Although RFA also yielded survival benefits, its effect was restricted to locally advanced tumors. MDPI 2022-03-23 /pmc/articles/PMC9029596/ /pubmed/35448156 http://dx.doi.org/10.3390/curroncol29040182 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Inoue, Tadahisa Naitoh, Itaru Kitano, Rena Ibusuki, Mayu Kobayashi, Yuji Sumida, Yoshio Nakade, Yukiomi Ito, Kiyoaki Yoneda, Masashi Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma |
title | Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma |
title_full | Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma |
title_fullStr | Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma |
title_full_unstemmed | Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma |
title_short | Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma |
title_sort | endobiliary radiofrequency ablation combined with gemcitabine and cisplatin in patients with unresectable extrahepatic cholangiocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029596/ https://www.ncbi.nlm.nih.gov/pubmed/35448156 http://dx.doi.org/10.3390/curroncol29040182 |
work_keys_str_mv | AT inouetadahisa endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT naitohitaru endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT kitanorena endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT ibusukimayu endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT kobayashiyuji endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT sumidayoshio endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT nakadeyukiomi endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT itokiyoaki endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma AT yonedamasashi endobiliaryradiofrequencyablationcombinedwithgemcitabineandcisplatininpatientswithunresectableextrahepaticcholangiocarcinoma |